Home » Newsletters » BioWorld Science

BioWorld Science

July 23, 1998

View Archived Issues

New antiasthma drug available for licensing from BTG

Inhaled analgesic available for licensing from BTG

Jenapharm describes scavestrogens, a novel class of nonfeminizing estrogens

Therapeutics for urinary incontinence in development at Dainippon

Sankyo prepares inhibitors of TNF-alpha production

Daiichi team discloses ICAM-1 production inhibitors for inflammatory disorders

Potent erythromycin derivatives for Gram-positive infections discovered by Taisho

Scientists at Takeda disclose inhibitors of Na+/H+ exchange

Novel antiallergic diamide compounds in the pipeline at Kowa

New series of neuroprotective compounds described by Nippon Chemiphar

FDA approves new dose range for Zocor

Use of Anticort in AIDS supported by new study

Nortran initiates phase II trials for local anesthetic

BioLon receives FDA approval

Phase III clinical trial results with galantamine suggest novel mechanism of action

MabThera now available for non-Hodgkin's lymphoma in the U.K.

Bristol-Myers Squibb now marketing Cefzil in U.K.

T-593 undergoes extensive toxicological evaluation

Preclinical activity and resistance profile of S-1153, a new NNRTI

New proton pump inhibitor synthesized and evaluated at Yung-Jin

Zelapar receives approval recommendation in U.K.

First antisense drug recommended for approval by FDA advisory committee

First clinical trial for obstructive sleep apnea completed

Genentech stroke study terminated due to inability to demonstrate clinical benefit

Canadian approval granted for first NNRTI for HIV/AIDS